News

Two Likely Biomarkers for PAH Diagnosis, Progression Identified

Two new biomarkers to assess pulmonary arterial hypertension (PAH) were discovered through large-scale analysis of gene activity profiles using computer software, a study reported. These biomarkers, the activity of the genes PNISR and HNRNPH1, may help diagnose PAH, monitor its progression, or measure responses to therapy. They also may highlight…

PAH Patients May Lack Enough of Some Key Vitamins, Minerals

People with pulmonary arterial hypertension (PAH) may lack some key vitamins and minerals their bodies need daily to stay healthy, which may lessen their vitality, according to a small study from the Netherlands. Besides the known lack of vitamin D and iron, researchers observed lower than recommended levels of…

Top 10 Pulmonary Hypertension Stories of 2022

Over the past year, the team here at Pulmonary Hypertension News has brought you up-to-date coverage of the latest developments in research, care, and treatment related to pulmonary hypertension (PH). We hope to continue to be a resource for the PH community in the coming year. Here is a…

Unhealthy Behaviors, Thoughts Can Cause Depression or Anxiety

Unhealthy changes in cognition, like a focus on worries, can lead to anxiety in people with pulmonary hypertension(PH), while those in behavior, like social avoidance, may cause depression, according to a U.K. study. Greater dyspnea, or shortness of breath, was also a contributing factor when paired with these cognitive or…

Combination Therapy Improves Blood Circulation, Analysis Suggests

Combination therapy — a treatment approach used to target multiple pathways involved in pulmonary arterial hypertension (PAH) — improves hemodynamics (blood flow) in treatment-naïve patients, according to a new pooled analysis of several studies. A measure of the resistance to blood flow, called pulmonary vascular resistance (PVR), decreased significantly…

Inhaled Treatment MK-5475 Shows Promise in Phase 1 Trial for PAH

Merck’s investigational inhaled treatment MK-5475 was well-tolerated and showed promise among adults with pulmonary arterial hypertension (PAH) in a Phase 1 clinical trial. Results showed that the therapy improved blood flow in patients’ lungs, but did not affect blood pressure elsewhere in the body. “The promising pulmonary selectivity and…

Treprostinil Infusion Pump for PAH Is Goal of New Collaboration

Liquidia and Sandoz will collaborate with Mainbridge Health Partners to develop a new subcutaneous or under-the-skin infusion pump for treprostinil — a generic form of Remodulin — for treating people with pulmonary arterial hypertension (PAH). The exclusive rights to promote and market treprostinil injection belong…

Inhaled Seralutinib Shows Potential to Treat PAH in Phase 2 Trial

Treatment with seralutinib (GB002), an inhaled investigational therapy, significantly improved measures of blood pressure in the lungs of people with pulmonary arterial hypertension (PAH) in the Phase 2 TORREY study, meeting the trial’s main goal. Promising effects also were seen on measures of exercise capacity and heart structure, with these…